Search
Mecamylamine
go.drugbank.com/drugs/DB00657ApprovedInvestigationalMecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … [L39140] It blocks the interaction between viral spike proteins and angiotensin-converting enzyme 2 (ACE2) that allows for viral entry into the cell, thereby inhibiting the virus' ability to replicate.
Insulin glulisine
go.drugbank.com/drugs/DB01309ApprovedInsulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes … This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid.
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIndalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMeperidine
go.drugbank.com/drugs/DB00454ApprovedInvestigationalA narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. … Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDulaglutide
go.drugbank.com/drugs/DB09045ApprovedInvestigationaltherapy to diet and exercise in the management of 2 diabetes (T2DM). … It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.[L34665]
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Calfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalIt adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant. … Calfactant has been shown to decrease the incidence of respiratory distress syndrome, mortality due to respiratory distress syndrome, and air leaks associated with respiratory distress syndrome in clinical
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIn November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements … Mafenide is a sulfonamide-type antimicrobial agent used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.